Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1315-1323

  Humpolikova Adamkova L ^a   Kovarik J ^a   Dusek L ^b   Lauerova L ^a   Boudny V ^a   Fait, V ^a   Fojtova M ^c   Krejci E ^a   Kovarik A ^c  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Disease outcome; Interferons; Malignant melanoma; STAT3 activation

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA2B INTERFERON; STAT1 PROTEIN; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CELL PROLIFERATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, INTERFERON ALPHA-BETA; RNA, MESSENGER; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 64049098682     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.009     Document Type: Article

References (37)

1. Agarwala S.S., and Kirkwood J.M. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol 2 (1995) 365-371
2. Kirkwood JM. Biologic therapy with interferon alpha and beta. Clinical applications: melanoma. In De Vita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Principles and Practice of oncology. Philadelphia: J.B. Lippincott; 1995. p. 388-411.
3. Price K.L., Herlyn M., Dent C.L., Gewert D.R., and Linge C. The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Res 15 (2005) 91-98
4. Hague S.J., and Williams B.R.G. Signal transduction in the Interferon System. Semin Oncol 25 (1998) 14-22
5. Schindler Ch. Cytokines and JAK-STAT signaling. Exp Cell Res 253 (1999) 7-14
6. Caraglia M., Marra M., Pelaia G., et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202 (2005) 323-335
7. Lens M. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatol Ther 19 (2006) 9-18
8. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
9. Greenhalg C.J., and Hilton D.J. Negative regulation of cytokine signaling. J Leukoc Biol 70 (2001) 348-356
10. Fujimoto M., and Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24 (2003) 659-666
11. Rawlings J.S., Rosler K.M., and Harrison D.A. The JAK/STAT signaling pathway. J Cell Sci 117 (2004) 1281-1283
12. Horvath C.M., Wen Z., and Darnell Jr. J.E. A Stat protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 9 (1995) 984-994
13. Seidel H.M., Milocco L.H., Lamb P., Darnell Jr. J.E., Stein R.B., and Rosen J. Spacing of palindromic half sites as a determinant of selective STAT DNA binding and transcriptional activity. Proc Natl Acad Sci USA 92 (1995) 3041-3045
14. Meraz M.A., White J.M., Sheehan K.C., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathways. Cell 84 (1996) 431-442
15. Levy D.E. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell Mol Life Sci 55 (1999) 1559-1567
16. Kovarik J., Boudny V., Kocak I., Lauerova L., Fait V., and Vagundova M. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 12 (2003) 335-340
17. Boudny V., Dusek L., Adamkova L., et al. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients. Neoplasma 52 (2005) 330-337
18. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
19. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 109 (2002) 1139-1142
20. Lesinski G.B., Treffry J., Brasdovich M., et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response of IFN- compared with immune effector cells. Clin Cancer Res 13 (2007) 5010-5019
21. Messina J.L., Hua Y., Riker A.I., Munster P.N., Jove R.L., and Daud A.I. Activated STAT-3 in melanoma. Cancer Control 15 (2008) 196-201
22. Darnell J.E. Validating Stat3 in cancer therapy. Nat Med 11 (2005) 595-596
23. Kiuchi N., Nakajima K., Ichiba M., et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 189 (1999) 63-73
24. Pansky A., Hildebrand P., Fasler-Kan E., et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85 (2000) 720-725
25. Boudny V., Kocak I., Lauerova L., and Kovarik J. Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. Folia Biol (Praha) 49 (2003) 142-146
26. Jackson D.P., Watling D., Rogers N.C., et al. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 13 (2003) 219-229
27. Lesinski G.B., Valentino D., Hade E.M., et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 54 (2005) 815-825
28. Kortylewski M., Komyod W., Kauffmann M.E., Bosserhoff A., Heinrich P.C., and Behrmann I. Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 122 (2004) 414-422
29. Calo V., Migliavacca M., Bazan V., et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197 (2003) 157-168
30. Carson W.E. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin Cancer Res 4 (1998) 2219-2228
31. Ramana C.V., Kumar A., and Enelow R. Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem Biophys Res Commun 327 (2005) 727-733
32. Kovarik A., Fojtova M., Boudny V., Adamkova L., Lauerova L., and Kovarik J. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res 15 (2005) 481-488
33. Fojtova M., Boudny V., Kovarik A., et al. Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br J Cancer 97 (2007) 231-237
34. Komyod W., Bohm M., Metze D., Heinrich P.C., and Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 5 (2007) 271-281
35. Kirkwood J.M., Strwaderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., and Blum R.H. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
36. Lens M.B., and Dawes M. Interferon alpha therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20 (2002) 1818-1825
37. Xie T.X., Huang F.J., Aldape K.D., et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 15 (2006) 3188-3196